Therapeutic complement inhibition: New developments

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 6, 2010, Pages 660-668

  Emlen, Woodruff ^a   Li, Wenhan ^b   Kirschfink, Michael ^b  

^a Taligen Therapeutics   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Complement; disease; drugs; inflammation; therapy

Indexed keywords

APT 070; ARC 1905; BLOOD CLOTTING INHIBITOR; CAB 2; CDX 1135; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5 MINIBODY; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; COMPLEMENT INHIBITOR; COMPSTATIN; ECULIZUMAB; FACTOR B ANTIBODY; FACTOR D ANTIBODY; MIROCOCEPT; MLN 2222; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; PMX 53; POT 4; PROPERDIN; RECOMBINANT PROTEIN; RHUCIN; SERINE PROTEINASE INHIBITOR; TA 106; TP 10; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; AUTOIMMUNE DISEASE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; EFFECTOR CELL; EUROPE; HEMOLYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY DISEASE; NONHUMAN; OSTEOARTHRITIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT INDICATION;

ANGIOEDEMAS, HEREDITARY; ANIMALS; ANTIBODIES, MONOCLONAL; COMPLEMENT ACTIVATION; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT SYSTEM PROTEINS; HUMANS;

EID: 77957567053     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1262888     Document Type: Review

References (46)

1. Walport M J. Complement. First of two parts. N Engl J Med 2001 344 (14) 1058-1066
2. Walport M J. Complement. Second of two parts. N Engl J Med 2001 344 (15) 1140-1144
3. Sjöberg A P., Trouw L A., Blom A M. Complement activation and inhibition: a delicate balance. Trends Immunol 2009 30 (2) 83-90
4. Markiewski M M., Lambris J D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007 171 (3) 715-727
5. Holers V M. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 2008 223 300-316
6. Nussenblatt R B., Liu B, Li Z. Age-related macular degeneration: an immunologically driven disease. Curr Opin Investig Drugs 2009 10 (5) 434-442
7. Ricklin D, Lambris J D. Complement-targeted therapeutics. Nat Biotechnol 2007 25 (11) 1265-1275
8. Mollnes T E., Kirschfink M. Strategies of therapeutic complement inhibition. Mol Immunol 2006 43 (1-2) 107-121
9. Davis A E. III. The pathophysiology of hereditary angioedema. Clin Immunol 2005 114 (1) 3-9
10. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009 15 (2) 69-78
11. Kirschfink M, Mollnes T E. C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother 2001 2 (7) 1073-1083
12. Beinrohr L, Dobó J, Závodszky P, Gál P. C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation. Trends Mol Med 2008 14 (12) 511-521
13. Müller-Eberhard H J. Molecular organization and function of the complement system. Annu Rev Biochem 1988 57 321-347
14. Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 2008 59 293-309
15. Taylor P R., Carugati A, Fadok V A. et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000 192 (3) 359-366
16. Botto M, Kirschfink M, Macor P, Pickering M C., Würzner R, Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol Immunol 2009 46 (14) 2774-2783
17. Thiel S, Gadjeva M. Humoral pattern recognition molecules: mannan-binding lectin and ficolins. Adv Exp Med Biol 2009 653 58-73
18. Undar A, Fraser C D. Jr. Anti-factor D monoclonal antibody, pulsatile flow and cardiotomy suction during cardiopulmonary bypass. Eur J Cardiothorac Surg 2002 22 (2) 330-331 discussion 331
19. Taube C, Thurman J M., Takeda K et al. Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci U S A 2006 103 (21) 8084-8089
20. Kemper C, Hourcade D E. Properdin: new roles in pattern recognition and target clearance. Mol Immunol 2008 45 (16) 4048-4056
21. Hourcade D E. Properdin and complement activation: a fresh perspective. Curr Drug Targets 2008 9 (2) 158-164
22. Gupta-Bansal R, Parent J B., Brunden K R. Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol 2000 37 (5) 191-201
23. Ricklin D, Lambris J D. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008 632 273-292
24. Sahu A, Morikis D, Lambris J D. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol 2003 39 (10) 557-566
25. Nilsson B, Larsson R, Hong J et al. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998 92 (5) 1661-1667
26. Lazar H L., Keilani T, Fitzgerald C A. et al, TP10 Cardiac Surgery Study Group. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation 2007 116 (11, Suppl) I83-I88
27. Hillmen P, Muus P, Dührsen U et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007 110 (12) 4123-4128
28. Dubois E A., Cohen A F. Eculizumab. Br J Clin Pharmacol 2009 68 (3) 318-319
29. Lappegård K T., Christiansen D, Pharo A et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci U S A 2009 106 (37) 15861-15866
30. Risitano A M., Notaro R, Marando L et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009 113 (17) 4094-4100
31. Patel S. Combination therapy for age-related macular degeneration. Retina 2009 29 (6, Suppl) S45-S48
32. Monk P N., Scola A M., Madala P, Fairlie D P. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007 152 (4) 429-448
33. Wills-Karp M. Complement activation pathways: a bridge between innate and adaptive immune responses in asthma. Proc Natl Acad Sci U S A 2007 4 (3) 247-251
34. Sheerin N S., Risley P, Abe K et al. Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB J 2008 22 (4) 1065-1072
35. Smith R A. Targeting anticomplement agents. Biochem Soc Trans 2002 30 (Pt 6) 1037-1041
36. Souza D G., Esser D, Bradford R, Vieira A T., Teixeira M M. APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 2005 145 (8) 1027-1034
37. Banz Y, Hess O M., Robson S C. et al. Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. Cardiovasc Res 2007 76 (3) 482-493
38. Szakonyi G, Guthridge J M., Li D, Young K, Holers V M., Chen X S. Structure of complement receptor 2 in complex with its C3d ligand. Science 2001 292 (5522) 1725-1728
39. Huang Y, Qiao F, Atkinson C, Holers V M., Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 2008 181 (11) 8068-8076
40. Atkinson C, Qiao F, Song H, Gilkeson G S., Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 2008 180 (2) 1231-1238
41. Song H, Qiao F, Atkinson C, Holers V M., Tomlinson S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol 2007 179 (11) 7860-7867
42. Rohrer B, Long Q, Coughlin B et al. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci 2009 50 (7) 3056-3064
43. Qiao F, Atkinson C, Song H, Pannu R, Singh I, Tomlinson S. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol 2006 169 (3) 1039-1047
44. Atkinson C, Song H, Lu B et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005 115 (9) 2444-2453
45. Seelen M A., Roos A, Wieslander J et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods 2005 296 (12) 187-198
46. Banda N K., Levitt B, Glogowska M J. et al. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol 2009 183 (9) 5928-5937